Ryuji Fukushima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryuji Fukushima has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Aritada Yoshimura
Animal Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
14 shared publicationsDaiki Hirao
Koganei Animal Emergency Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
11 shared publicationsTakahiro Ohmori
Koganei Animal Emergency Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
9 shared publicationsShohei Morita
Koganei Animal Emergency Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
8 shared publicationsShusaku Yamada
Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
6 shared publicationsTakae Kawaguchi
Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
6 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 88  (2) , 222-226
37,X/38,XY mosaicism in a cat with a female phenotype and an enlarged clitoris
A 10-month-old mixed-breed cat was presenting a female appearance; however, a detailed examination of external genitalia revealed an enlarged clitoris with spines. The urethra opened into the vagina. Laparotomy and subsequent histopathological examination revealed that both ovaries were replaced by hypoplastic testes, with underdeveloped uteruses located caudal to them. Chromosome and genetic testing using peripheral blood revealed that the cat displayed a nearly 1:1 mosaicism of the 37,X and 38,XY chromosomes and presence of the SRY gene. Only two cases of 37,X/38,XY mosaicism have been reported in cats, both displaying a normal penis and prepuce, indicating a male phenotype. To the best of our knowledge, this is the first report of 37,X and 38,XY mosaicism manifesting as a female phenotype.
- 1 January 2026
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 88  (2) , 222-226
Open Access37,X/38,XY mosaicism in a cat with a female phenotype and an enlarged clitoris
A 10-month-old mixed-breed cat was presenting a female appearance; however, a detailed examination of external genitalia revealed an enlarged clitoris with spines. The urethra opened into the vagina. Laparotomy and subsequent histopathological examination revealed that both ovaries were replaced by hypoplastic testes, with underdeveloped uteruses located caudal to them. Chromosome and genetic testing using peripheral blood revealed that the cat displayed a nearly 1:1 mosaicism of the 37,X and 38,XY chromosomes and presence of the SRY gene. Only two cases of 37,X/38,XY mosaicism have been reported in cats, both displaying a normal penis and prepuce, indicating a male phenotype. To the best of our knowledge, this is the first report of 37,X and 38,XY mosaicism manifesting as a female phenotype.
- Open Access
- 1 January 2025
- Published by ScopeMed in Open Veterinary Journal
- Vol. 15  (11) , 6020
Systemic gene expression mapping of voltage-gated calcium channel α1-subunits in cats
Background: In veterinary medicine, voltage-gated calcium channels (VGCCs) are key drug targets. Calcium channel blockers (CCBs) are the standard treatment for common feline diseases, such as systemic hypertension and hypertrophic cardiomyopathy. However, therapeutic strategies are limited due to the adverse effects of existing drugs like amlodipine, such as activation of the renin-angiotensin-aldosterone system. A critical lack of feline-specific data on the tissue distribution of VGCC subtypes fundamentally hinders the safe and effective application of CCBs in cats. This is because knowledge from other species is often not translatable due to the unique metabolic pathways in cats. Aim: To fill this critical data gap, the present study created the first baseline quantitative map of the mRNA expression of seven major VGCC α1-subunits across a comprehensive range of feline tissues. Methods: Twelve tissue types were collected from a single 16-month-old male cat. Using a validated TaqMan probe-based quantitative real-time PCR assay, we measured the relative mRNA expression of seven CaV α1-subunit genes: CACNA1S (CaV1.1), CACNA1C (CaV1.2), CACNA1D (CaV1.3), CACNA1F (CaV1.4), CACNA1B (CaV2.2), CACNA1G (CaV3.1), and CACNA1H (CaV3.2). Relative transcript abundance was calculated using the 2-ΔCt method with 18S rRNA as the endogenous control for normalization. Results: The seven VGCC genes exhibited distinct, tissue-specific expression patterns. CACNA1S expression was predominantly localized to skeletal muscle. The heart showed the highest expression of CACNA1C and CACNA1H. The brain displayed prominent CACNA1B, CACNA1C, and CACNA1G expression. The mesenteric lymph node also showed significant CACNA1C, CACNA1F, and CACNA1G expression. Conversely, the liver and pancreas consistently displayed very low expression for most of the channel genes investigated. Conclusion: This study provides the first foundational mRNA expression map of major VGCC α1-subunits in feline tissues. The results reveal unique expression profiles that highlight both conserved physiological functions and significant differences compared to other species, particularly in cardiac and lymphoid tissues. These molecular data are vital for advancing feline pharmacology by enabling more accurate predictions of the therapeutic and adverse effects of CCBs and provide a critical resource for future investigations into feline channelopathies.
- 1 January 2025
- Published by ScopeMed in Open Veterinary Journal
- Vol. 15  (11) , 6020
Open AccessSystemic gene expression mapping of voltage-gated calcium channel α1-subunits in cats
Background: In veterinary medicine, voltage-gated calcium channels (VGCCs) are key drug targets. Calcium channel blockers (CCBs) are the standard treatment for common feline diseases, such as systemic hypertension and hypertrophic cardiomyopathy. However, therapeutic strategies are limited due to the adverse effects of existing drugs like amlodipine, such as activation of the renin-angiotensin-aldosterone system. A critical lack of feline-specific data on the tissue distribution of VGCC subtypes fundamentally hinders the safe and effective application of CCBs in cats. This is because knowledge from other species is often not translatable due to the unique metabolic pathways in cats. Aim: To fill this critical data gap, the present study created the first baseline quantitative map of the mRNA expression of seven major VGCC α1-subunits across a comprehensive range of feline tissues. Methods: Twelve tissue types were collected from a single 16-month-old male cat. Using a validated TaqMan probe-based quantitative real-time PCR assay, we measured the relative mRNA expression of seven CaV α1-subunit genes: CACNA1S (CaV1.1), CACNA1C (CaV1.2), CACNA1D (CaV1.3), CACNA1F (CaV1.4), CACNA1B (CaV2.2), CACNA1G (CaV3.1), and CACNA1H (CaV3.2). Relative transcript abundance was calculated using the 2-ΔCt method with 18S rRNA as the endogenous control for normalization. Results: The seven VGCC genes exhibited distinct, tissue-specific expression patterns. CACNA1S expression was predominantly localized to skeletal muscle. The heart showed the highest expression of CACNA1C and CACNA1H. The brain displayed prominent CACNA1B, CACNA1C, and CACNA1G expression. The mesenteric lymph node also showed significant CACNA1C, CACNA1F, and CACNA1G expression. Conversely, the liver and pancreas consistently displayed very low expression for most of the channel genes investigated. Conclusion: This study provides the first foundational mRNA expression map of major VGCC α1-subunits in feline tissues. The results reveal unique expression profiles that highlight both conserved physiological functions and significant differences compared to other species, particularly in cardiac and lymphoid tissues. These molecular data are vital for advancing feline pharmacology by enabling more accurate predictions of the therapeutic and adverse effects of CCBs and provide a critical resource for future investigations into feline channelopathies.
- Open Access
- 1 January 2025
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 87  (12) , 1398-1404
Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia
Supraventricular tachyarrhythmia (SVTA) in dogs can cause cardiac dysfunction and may progress to heart failure. Pimobendan, an inotropic agent with calcium-sensitizing and phosphodiesterase III inhibition, is widely used in veterinary medicine. However, its influence on myocardial injury under persistent SVTA remains incompletely understood. This study aimed to evaluate whether pimobendan improves systolic function without exacerbating myocardial injury, using a canine model of rapid atrial pacing (RAP). Fourteen healthy Beagle dogs were allocated to either a control or pimobendan group. RAP was performed for three weeks at 390 bpm. Cardiac function was assessed by echocardiography before (baseline) and after RAP (3W). Concurrently, cardiac troponin I (cTnI) concentrations were measured to assess myocardial injury. In the control group, a significant increase in cTnI was observed at 3W compared with baseline (0.023 ± 0.029 ng/mL vs. 0.176 ± 0.173 ng/mL). Additionally, in the control group, echocardiographic parameters worsened, including fractional shortening (FS) (37.8 ± 4.6% vs. 24.5 ± 6.8%) and stroke volume (SV) (15.8 ± 3.1 mL vs. 10.5 ± 2.0 mL) at 3W compared with baseline. In contrast, the pimobendan group showed no significant differences in these echocardiographic parameters. cTnI concentrations also remained within the normal range without significant differences. These results suggest that pimobendan preserved systolic function without aggravating myocardial injury during sustained SVTA. Pimobendan may therefore be safe and effective cardiac inotropic agent for the treatment of dogs with SVTA.
- 1 January 2025
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 87  (12) , 1398-1404
Open AccessEffect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia
Supraventricular tachyarrhythmia (SVTA) in dogs can cause cardiac dysfunction and may progress to heart failure. Pimobendan, an inotropic agent with calcium-sensitizing and phosphodiesterase III inhibition, is widely used in veterinary medicine. However, its influence on myocardial injury under persistent SVTA remains incompletely understood. This study aimed to evaluate whether pimobendan improves systolic function without exacerbating myocardial injury, using a canine model of rapid atrial pacing (RAP). Fourteen healthy Beagle dogs were allocated to either a control or pimobendan group. RAP was performed for three weeks at 390 bpm. Cardiac function was assessed by echocardiography before (baseline) and after RAP (3W). Concurrently, cardiac troponin I (cTnI) concentrations were measured to assess myocardial injury. In the control group, a significant increase in cTnI was observed at 3W compared with baseline (0.023 ± 0.029 ng/mL vs. 0.176 ± 0.173 ng/mL). Additionally, in the control group, echocardiographic parameters worsened, including fractional shortening (FS) (37.8 ± 4.6% vs. 24.5 ± 6.8%) and stroke volume (SV) (15.8 ± 3.1 mL vs. 10.5 ± 2.0 mL) at 3W compared with baseline. In contrast, the pimobendan group showed no significant differences in these echocardiographic parameters. cTnI concentrations also remained within the normal range without significant differences. These results suggest that pimobendan preserved systolic function without aggravating myocardial injury during sustained SVTA. Pimobendan may therefore be safe and effective cardiac inotropic agent for the treatment of dogs with SVTA.
- Open Access
- 1 January 2025
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 87  (5) , 454-457
Long-term management of paroxysmal atrioventricular block with Wenckebach cycles in a dog
This is the first report of paroxysmal atrioventricular block with Wenckebach cycles in a dog exhibiting syncope. The patient was a 1-year-old female Shiba Inu referred to our hospital with chief complaints of exercise intolerance, dizziness during walking, and tongue discoloration. Pacemaker implantation was performed based on the clinical presentation and Holter electrocardiogram findings. In this case, long-term management was successfully achieved for 13 years and 3 months (Age 15 years old) after the placement of pacemaker. A histopathological examination revealed that no abnormalities in the conduction system were detected that could explain the arrhythmia. Consequently, the arrhythmia was suspected to have been caused by vagus nerve stimulation.
- 1 January 2025
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 87  (5) , 454-457
Open AccessLong-term management of paroxysmal atrioventricular block with Wenckebach cycles in a dog
This is the first report of paroxysmal atrioventricular block with Wenckebach cycles in a dog exhibiting syncope. The patient was a 1-year-old female Shiba Inu referred to our hospital with chief complaints of exercise intolerance, dizziness during walking, and tongue discoloration. Pacemaker implantation was performed based on the clinical presentation and Holter electrocardiogram findings. In this case, long-term management was successfully achieved for 13 years and 3 months (Age 15 years old) after the placement of pacemaker. A histopathological examination revealed that no abnormalities in the conduction system were detected that could explain the arrhythmia. Consequently, the arrhythmia was suspected to have been caused by vagus nerve stimulation.
- Open Access
- 30 March 2024
- Published by MDPI AG in Veterinary Sciences
- Vol. 11  (4) , 155
Effects of Beraprost with or without NOS Inhibition on Plasma Aldosterone and Hemodynamics in Healthy Cats
Objectives: The aim of the study was to evaluate the hemodynamic and RA system effects of the oral administration of the clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess the plasma aldosterone and renin concentrations (PAC and PRC), blood pressure, heart rate, and exploratorily to estimate renal plasma flow (RPF) and renal vascular resistance (RVR) with simplified methods. Results: Beraprost reduced PAC when compared to the placebo (p < 0.05); this was reversed when NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was added to the beraprost treatment (p < 0.01). No differences in the PRC or hemodynamic parameters were detected between beraprost and the placebo. The correlation ratios (η2) showed opposite relationships between beraprost and the added L-NAME effects on PAC, mean blood pressure (MBP), heart rate, estimated RPF (p < 0.001), estimated RVR (p < 0.01), and PRC (p < 0.05). Conclusions: In healthy cats, the clinical dose of beraprost suppresses PAC, which can be reversed by the inhibition of NOS.
- 30 March 2024
- Published by MDPI AG in Veterinary Sciences
- Vol. 11  (4) , 155
Open AccessEffects of Beraprost with or without NOS Inhibition on Plasma Aldosterone and Hemodynamics in Healthy Cats
Objectives: The aim of the study was to evaluate the hemodynamic and RA system effects of the oral administration of the clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess the plasma aldosterone and renin concentrations (PAC and PRC), blood pressure, heart rate, and exploratorily to estimate renal plasma flow (RPF) and renal vascular resistance (RVR) with simplified methods. Results: Beraprost reduced PAC when compared to the placebo (p < 0.05); this was reversed when NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was added to the beraprost treatment (p < 0.01). No differences in the PRC or hemodynamic parameters were detected between beraprost and the placebo. The correlation ratios (η2) showed opposite relationships between beraprost and the added L-NAME effects on PAC, mean blood pressure (MBP), heart rate, estimated RPF (p < 0.001), estimated RVR (p < 0.01), and PRC (p < 0.05). Conclusions: In healthy cats, the clinical dose of beraprost suppresses PAC, which can be reversed by the inhibition of NOS.
- Open Access
- 1 January 2024
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 86  (12) , 1233-1236
Situational syncope caused by vomiting in a cat
A 14-year-old spayed female mixed-breed cat weighing 3.4 kg was admitted to the Tokyo University of Agriculture and Technology Animal Medical Center for syncope after vomiting. Echocardiography, electrocardiography, and thoracic radiography revealed no abnormalities. Holter electrocardiography showed a paroxysmal high-grade atrioventricular block coinciding with the vomiting. Based on these findings, the cat was diagnosed as having situational syncope with paroxysmal high-grade atrioventricular block triggered by vomiting, which improved with antiemetic treatment alone. The cat subsequently died of chronic kidney disease approximately 3 years and 4 months after the initial diagnosis. This is the first reported case of situational syncope triggered by vomiting in a cat.
- 1 January 2024
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 86  (12) , 1233-1236
Open AccessSituational syncope caused by vomiting in a cat
A 14-year-old spayed female mixed-breed cat weighing 3.4 kg was admitted to the Tokyo University of Agriculture and Technology Animal Medical Center for syncope after vomiting. Echocardiography, electrocardiography, and thoracic radiography revealed no abnormalities. Holter electrocardiography showed a paroxysmal high-grade atrioventricular block coinciding with the vomiting. Based on these findings, the cat was diagnosed as having situational syncope with paroxysmal high-grade atrioventricular block triggered by vomiting, which improved with antiemetic treatment alone. The cat subsequently died of chronic kidney disease approximately 3 years and 4 months after the initial diagnosis. This is the first reported case of situational syncope triggered by vomiting in a cat.
- Open Access
- 1 January 2024
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 86  (5) , 533-541
Use of amlodipine in the treatment of cats with systemic hypertension in Japan
An increase in systemic blood pressure causes bleeding and ischemia owing to peripheral vascular breakdown, leading to various forms of organ damage. The brain, eyes, kidneys, and cardiovascular system are known target organs for hypertension. To our knowledge, no reports in Japan describe, in detail, the types of antihypertensive drugs used to treat hypertension in cats or its underlying causes. Therefore, we aimed to investigate the use of antihypertensive drugs in domestic cats with hypertension in Japan, the causes of hypertension, and the vital prognosis of these patients. In the present survey, we found that amlodipine was used alone (60/80 cats) or concomitantly (20/80 cats) in all cat patients with hypertension in Japan. We also determined that blood pressure measurements were not yet routinely performed on cats at veterinary clinics in Japan. Furthermore, we have new information suggesting that amlodipine administration in cats with hypertension, which lowers systolic arterial pressure levels to within the normal range (<140 mmHg), may have a negative impact on their survival. Routine blood pressure measurements for cats during their regular health checkups can help identify hypertension, and proper interpretation of blood pressure readings can facilitate suitable treatment measures.
- 1 January 2024
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 86  (5) , 533-541
Open AccessUse of amlodipine in the treatment of cats with systemic hypertension in Japan
An increase in systemic blood pressure causes bleeding and ischemia owing to peripheral vascular breakdown, leading to various forms of organ damage. The brain, eyes, kidneys, and cardiovascular system are known target organs for hypertension. To our knowledge, no reports in Japan describe, in detail, the types of antihypertensive drugs used to treat hypertension in cats or its underlying causes. Therefore, we aimed to investigate the use of antihypertensive drugs in domestic cats with hypertension in Japan, the causes of hypertension, and the vital prognosis of these patients. In the present survey, we found that amlodipine was used alone (60/80 cats) or concomitantly (20/80 cats) in all cat patients with hypertension in Japan. We also determined that blood pressure measurements were not yet routinely performed on cats at veterinary clinics in Japan. Furthermore, we have new information suggesting that amlodipine administration in cats with hypertension, which lowers systolic arterial pressure levels to within the normal range (<140 mmHg), may have a negative impact on their survival. Routine blood pressure measurements for cats during their regular health checkups can help identify hypertension, and proper interpretation of blood pressure readings can facilitate suitable treatment measures.
- Open Access
- 30 September 2023
- Published by MDPI AG in Preprints.org
Effects of Beraprost with or without NOS Inhibitor on Aldosterone and Hemodynamics in Healthy Cats
Objectives: The aim of the study was to evaluate the effects of oral administration of clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess plasma aldosterone and renin concentrations, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance. Results: Beraprost reduced plasma aldosterone when compared to the placebo (P < 0.05); this was reversed when NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was added to beraprost treatment (P < 0.01). No differences in the plasma renin concentration or hemodynamic parameters were detected between beraprost and placebo. The correlation ratios (η2) showed opposite relationships between beraprost and added L-NAME effects on aldosterone concentration, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance (P < 0.001). Conclusions: In healthy cats, the clinical dose of beraprost suppresses plasma concentration of aldosterone, which can be reversed by inhibition of NOS.
- 30 September 2023
- Published by MDPI AG in Preprints.org
Open AccessEffects of Beraprost with or without NOS Inhibitor on Aldosterone and Hemodynamics in Healthy Cats
Objectives: The aim of the study was to evaluate the effects of oral administration of clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess plasma aldosterone and renin concentrations, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance. Results: Beraprost reduced plasma aldosterone when compared to the placebo (P < 0.05); this was reversed when NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was added to beraprost treatment (P < 0.01). No differences in the plasma renin concentration or hemodynamic parameters were detected between beraprost and placebo. The correlation ratios (η2) showed opposite relationships between beraprost and added L-NAME effects on aldosterone concentration, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance (P < 0.001). Conclusions: In healthy cats, the clinical dose of beraprost suppresses plasma concentration of aldosterone, which can be reversed by inhibition of NOS.
- Open Access
- 1 January 2023
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 85  (5) , 541-545
A case of a dog with paragonimiasis after consumption of raw deer meat
A 6-year-old castrated male Cavalier King Charles Spaniel was referred to the Animal Medical Center, Tokyo University of Agriculture and Technology, for examination and treatment of recurrent pneumothorax. Chest radiography and computed tomography showed multiple cavitary lesions in the caudal right posterior lobe. These lesions were surgically excised via thoracotomy. Subsequent histopathological examination revealed paragonimiasis. In the postoperative review, we found that the owner had fed raw deer meat to the dog four months earlier. Deer meat has attracted attention as a source of Paragonimus in humans. To our knowledge, this is the first report of Paragonimus infection in a dog due to deer meat consumption.
- 1 January 2023
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 85  (5) , 541-545
Open AccessA case of a dog with paragonimiasis after consumption of raw deer meat
A 6-year-old castrated male Cavalier King Charles Spaniel was referred to the Animal Medical Center, Tokyo University of Agriculture and Technology, for examination and treatment of recurrent pneumothorax. Chest radiography and computed tomography showed multiple cavitary lesions in the caudal right posterior lobe. These lesions were surgically excised via thoracotomy. Subsequent histopathological examination revealed paragonimiasis. In the postoperative review, we found that the owner had fed raw deer meat to the dog four months earlier. Deer meat has attracted attention as a source of Paragonimus in humans. To our knowledge, this is the first report of Paragonimus infection in a dog due to deer meat consumption.
- Open Access
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 9, 954295
Efficacy of cilostazol in canine bradyarrhythmia
Recently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs with bradyarrhythmia in Japan. Dogs that had been brought to the Tokyo University of Agriculture and Technology Animal Medical Center and 23 veterinary hospitals in Japan and been treated with cilostazol initially as the only therapeutic strategy for bradyarrhythmia between January 2010 and August 2021 were included in this study. Survival analyses were performed using Cox proportional hazards analysis, the log-rank test, and the generalized Wilcoxon test to evaluate the efficacy of cilostazol. Fifty-nine privately owned dogs were included in this study. In the survival time analysis, the risk of death was significantly lower and the survival rate was higher in cases in which cilostazol was administered at 10 mg/kg or more per dose. A third-degree atrioventricular block also significantly increased the risk of death and was associated with a lower survival rate. However, in some patients with a third-degree atrioventricular block, there was an increase in the ventricular rate and improvement in clinical symptoms without disappearance or decrease of the atrioventricular block. This study had several important findings that have not previously been reported concerning the use of cilostazol for canine bradyarrhythmia, including the appropriate dose in a clinical setting and the efficacy and prognosis according to the type of bradyarrhythmia.
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 9, 954295
Open AccessEfficacy of cilostazol in canine bradyarrhythmia
Recently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs with bradyarrhythmia in Japan. Dogs that had been brought to the Tokyo University of Agriculture and Technology Animal Medical Center and 23 veterinary hospitals in Japan and been treated with cilostazol initially as the only therapeutic strategy for bradyarrhythmia between January 2010 and August 2021 were included in this study. Survival analyses were performed using Cox proportional hazards analysis, the log-rank test, and the generalized Wilcoxon test to evaluate the efficacy of cilostazol. Fifty-nine privately owned dogs were included in this study. In the survival time analysis, the risk of death was significantly lower and the survival rate was higher in cases in which cilostazol was administered at 10 mg/kg or more per dose. A third-degree atrioventricular block also significantly increased the risk of death and was associated with a lower survival rate. However, in some patients with a third-degree atrioventricular block, there was an increase in the ventricular rate and improvement in clinical symptoms without disappearance or decrease of the atrioventricular block. This study had several important findings that have not previously been reported concerning the use of cilostazol for canine bradyarrhythmia, including the appropriate dose in a clinical setting and the efficacy and prognosis according to the type of bradyarrhythmia.